Johannes Nagelschmitz

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Johannes Nagelschmitz, Martin Blunck, Joern Kraetzschmar et al. · Clinical Pharmacology Advances and Applications · 2014 · 126 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

First Assessment in Humans of the Safety, Tolerability, Pharmacokinetics, and Ex Vivo Pharmacodynamic Antimalarial Activity of the New Artemisinin Derivative Artemisone

Johannes Nagelschmitz, Barbara Voith, Georg Wensing et al. · Antimicrobial Agents and Chemotherapy · 2008 · 96 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen et al. · Clinical Drug Investigation · 2013 · 86 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial

Henrik Watz, Johannes Nagelschmitz, Anne Kirsten et al. · Pulmonary Pharmacology & Therapeutics · 2019 · 69 citations

Medicine, Pharmacotherapy, Pulmonology +6

Tolerability and Pharmacokinetic Properties of Ciprofloxacin Dry Powder for Inhalation in Patients With Cystic Fibrosis: A Phase I, Randomized, Dose-Escalation Study

Boris Weimann, Johannes Nagelschmitz, Claudia Rolinck‐Werninghaus et al. · Clinical Therapeutics · 2013 · 63 citations

Pharmacy, Pharmacokinetics, Pharmacology +17